Docetaxel Loaded PEG-PLGA Nanoparticles: Optimized Drug Loading, In-vitro Cytotoxicity and In-vivo Antitumor Effect.

Area of Science:

• Nanotechnology
• Materials Science
• Pharmacology

Background:

• Docetaxel (DTX) is a potent chemotherapeutic agent with limited efficacy due to poor solubility and systemic toxicity.
• Developing effective drug delivery systems is crucial for enhancing DTX's therapeutic index.
• Nanoparticles offer a promising platform for targeted drug delivery and improved pharmacokinetics.

Purpose of the Study:

• To optimize docetaxel (DTX)-loaded poly(lactic-co-glycolic acid)-polyethylene glycol (PLGA-PEG) nanoparticles using a Box-Behnken design.
• To evaluate the in-vitro cytotoxicity and in-vivo antitumor efficacy of the optimized DTX-loaded nanoparticles.
• To establish a potentially useful nanoparticle delivery system for DTX as an anticancer agent.

Main Methods:

• A 3-factor, 3-level Box-Behnken design was employed to optimize nanoparticle formulation.
• Independent variables included polymer concentration, drug concentration, and solvent ratio.
• Responses measured were particle size, poly dispersity index (PDI), and drug loading.
• Cytotoxicity was assessed using MTT assay on SKOV3 tumor cell lines.
• In-vivo antitumor efficacy was evaluated in tumor-bearing female BALB/c mice.

Main Results:

• Optimized nanoparticles achieved a particle size of 188 nm, PDI of 0.16, and drug loading of 9%.
• The in-vitro release profile exhibited an initial burst release followed by sustained drug release over 288 hours.
• DTX-loaded nanoparticles showed significantly greater cytotoxicity against SKOV3 cancer cells compared to free DTX.
• Enhanced tumor suppression was observed in vivo with the optimized DTX-loaded PEG-PLGA nanoparticles.

Conclusions:

• The optimized docetaxel-loaded PEG-PLGA nanoparticles represent a promising drug delivery system.
• This formulation enhances the anticancer potential of docetaxel through improved cytotoxicity and in-vivo efficacy.
• The developed nanoparticles offer a viable strategy for advancing docetaxel-based cancer therapy.